{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:38:55Z","timestamp":1767339535631,"version":"3.37.3"},"reference-count":53,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":138,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA177995-01A1"],"award-info":[{"award-number":["R01 CA177995-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast J"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1111\/tbj.12418","type":"journal-article","created":{"date-parts":[[2015,4,16]],"date-time":"2015-04-16T10:19:30Z","timestamp":1429179570000},"page":"377-386","source":"Crossref","is-referenced-by-count":31,"title":["Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ"],"prefix":"10.1155","volume":"21","author":[{"given":"Laura L.","family":"Reimers","sequence":"first","affiliation":[{"name":"Department of Epidemiology; Mailman School of Public Health; Columbia University; New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parijatham S.","family":"Sivasubramanian","sequence":"additional","affiliation":[{"name":"Department of Medicine; College of Physicians & Surgeons; Columbia University; New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn","family":"Hershman","sequence":"additional","affiliation":[{"name":"Department of Epidemiology; Mailman School of Public Health; Columbia University; New York New York"},{"name":"Department of Medicine; College of Physicians & Surgeons; Columbia University; New York New York"},{"name":"Herbert Irving Comprehensive Cancer Center; Columbia University; New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Beth","family":"Terry","sequence":"additional","affiliation":[{"name":"Department of Epidemiology; Mailman School of Public Health; Columbia University; New York New York"},{"name":"Herbert Irving Comprehensive Cancer Center; Columbia University; New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Greenlee","sequence":"additional","affiliation":[{"name":"Department of Epidemiology; Mailman School of Public Health; Columbia University; New York New York"},{"name":"Herbert Irving Comprehensive Cancer Center; Columbia University; New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Medicine; College of Physicians & Surgeons; Columbia University; New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Kalinsky","sequence":"additional","affiliation":[{"name":"Department of Medicine; College of Physicians & Surgeons; Columbia University; New York New York"},{"name":"Herbert Irving Comprehensive Cancer Center; Columbia University; New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Maurer","sequence":"additional","affiliation":[{"name":"Department of Medicine; College of Physicians & Surgeons; Columbia University; New York New York"},{"name":"Herbert Irving Comprehensive Cancer Center; Columbia University; New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramona","family":"Jayasena","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center; Columbia University; New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossy","family":"Sandoval","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center; Columbia University; New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center; Columbia University; New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine D.","family":"Crew","sequence":"additional","affiliation":[{"name":"Department of Epidemiology; Mailman School of Public Health; Columbia University; New York New York"},{"name":"Department of Medicine; College of Physicians & Surgeons; Columbia University; New York New York"},{"name":"Herbert Irving Comprehensive Cancer Center; Columbia University; New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,4,16]]},"reference":[{"key":"10.1111\/tbj.12418-BIB0001|tbj12418-cit-0001","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1158\/1055-9965.EPI-10-0835","article-title":"Integrating tools for breast cancer risk assessment, risk reduction, and early detection","volume":"19","author":"Ward","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1111\/tbj.12418-BIB0002|tbj12418-cit-0002","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/jnci\/95.7.526","article-title":"Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention","volume":"95","author":"Freedman","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/tbj.12418-BIB0003|tbj12418-cit-0003","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/tbj.12418-BIB0004|tbj12418-cit-0004","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","article-title":"Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study","volume":"97","author":"Fisher","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/tbj.12418-BIB0005|tbj12418-cit-0005","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jnci\/djk050","article-title":"Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial","volume":"99","author":"Powles","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/tbj.12418-BIB0006|tbj12418-cit-0006","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/jnci\/djk154","article-title":"Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy","volume":"99","author":"Veronesi","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/tbj.12418-BIB0007|tbj12418-cit-0007","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/jnci\/djk049","article-title":"Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial","volume":"99","author":"Cuzick","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/tbj.12418-BIB0008|tbj12418-cit-0008","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0140-6736(13)60140-3","article-title":"Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data","volume":"381","author":"Cuzick","year":"2013","journal-title":"Lancet"},{"key":"10.1111\/tbj.12418-BIB0009|tbj12418-cit-0009","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0140-6736(99)05036-9","article-title":"Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial","volume":"353","author":"Fisher","year":"1999","journal-title":"Lancet"},{"key":"10.1111\/tbj.12418-BIB0010|tbj12418-cit-0010","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/jnci\/djr027","article-title":"Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS","volume":"103","author":"Wapnir","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/tbj.12418-BIB0011|tbj12418-cit-0011","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0140-6736(03)13859-7","article-title":"Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial","volume":"362","author":"Houghton","year":"2003","journal-title":"Lancet"},{"key":"10.1111\/tbj.12418-BIB0012|tbj12418-cit-0012","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(11)70030-4","article-title":"Preventive therapy for breast cancer: a consensus statement","volume":"12","author":"Cuzick","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1111\/tbj.12418-BIB0013|tbj12418-cit-0013","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/tbj.12418-BIB0014|tbj12418-cit-0014","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","article-title":"Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene","volume":"96","author":"Martino","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/tbj.12418-BIB0015|tbj12418-cit-0015","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","article-title":"Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer","volume":"3","author":"Vogel","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1111\/tbj.12418-BIB0016|tbj12418-cit-0016","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/tbj.12418-BIB0017|tbj12418-cit-0017","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-158-8-201304160-00005","article-title":"Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force","volume":"158","author":"Nelson","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1111\/tbj.12418-BIB0018|tbj12418-cit-0018","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1200\/JCO.2008.20.5179","article-title":"American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction","volume":"27","author":"Visvanathan","year":"2009","journal-title":"J Clin Oncol"},{"volume-title":"NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Risk Reduction","year":"2012","author":"Bevers","key":"10.1111\/tbj.12418-BIB0019|tbj12418-cit-0019"},{"key":"10.1111\/tbj.12418-BIB0020|tbj12418-cit-0020","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1200\/JCO.2009.27.8077","article-title":"Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis","volume":"28","author":"Ropka","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12418-BIB0021|tbj12418-cit-0021","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1158\/1940-6207.CAPR-10-0100","article-title":"The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention","volume":"3","author":"Ravdin","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1111\/tbj.12418-BIB0022|tbj12418-cit-0022","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ypmed.2004.09.041","article-title":"Factors affecting breast cancer risk reduction practices among California physicians","volume":"41","author":"Kaplan","year":"2005","journal-title":"Prev Med"},{"key":"10.1111\/tbj.12418-BIB0023|tbj12418-cit-0023","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1200\/JOP.2010.000107","article-title":"Implementation in a large health system of a program to identify women at high risk for breast cancer","volume":"7","author":"Owens","year":"2011","journal-title":"Journal of Oncology Practice."},{"key":"10.1111\/tbj.12418-BIB0024|tbj12418-cit-0024","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","article-title":"Projecting individualized probabilities of developing breast cancer for white females who are being examined annually","volume":"81","author":"Gail","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/tbj.12418-BIB0025|tbj12418-cit-0025","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1186\/bcr2453","article-title":"Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting","volume":"11","author":"Habel","year":"2009","journal-title":"Breast Cancer Res"},{"key":"10.1111\/tbj.12418-BIB0026|tbj12418-cit-0026","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1200\/JCO.2006.10.2699","article-title":"Impact of randomized clinical trial results in the national comprehensive cancer network on the use of tamoxifen after breast surgery for ductal carcinoma in situ","volume":"25","author":"Yen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12418-BIB0027|tbj12418-cit-0027","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1158\/1055-9965.EPI-09-0930","article-title":"Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women","volume":"19","author":"Waters","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1111\/tbj.12418-BIB0028|tbj12418-cit-0028","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s10549-012-2089-2","article-title":"Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010","volume":"134","author":"Waters","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1111\/tbj.12418-BIB0029|tbj12418-cit-0029","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1370\/afm.284","article-title":"Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump","volume":"3","author":"Taylor","year":"2005","journal-title":"Ann Fam Med."},{"key":"10.1111\/tbj.12418-BIB0030|tbj12418-cit-0030","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s10434-001-0580-9","article-title":"Patient reluctance toward tamoxifen use for breast cancer primary prevention","volume":"8","author":"Port","year":"2001","journal-title":"Ann Surg Oncol"},{"key":"10.1111\/tbj.12418-BIB0031|tbj12418-cit-0031","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s10549-011-1450-1","article-title":"Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid","volume":"127","author":"Fagerlin","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1111\/tbj.12418-BIB0032|tbj12418-cit-0032","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10549-009-0618-4","article-title":"Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid","volume":"119","author":"Fagerlin","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1111\/tbj.12418-BIB0033|tbj12418-cit-0033","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10549-010-0845-8","article-title":"Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial","volume":"121","author":"Loehberg","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1111\/tbj.12418-BIB0034|tbj12418-cit-0034","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.1200\/JCO.2004.05.192","article-title":"Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors","volume":"22","author":"Bober","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12418-BIB0035|tbj12418-cit-0035","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1200\/JCO.2007.13.6739","article-title":"Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users","volume":"26","author":"Rondanina","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12418-BIB0036|tbj12418-cit-0036","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10549-010-0869-0","article-title":"Change in lifestyle behaviors and medication use after a diagnosis of ductal carcinoma in situ","volume":"124","author":"Sprague","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1111\/tbj.12418-BIB0037|tbj12418-cit-0037","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/cncr.20205","article-title":"Acceptance of tamoxifen chemoprevention by physicians and women at risk","volume":"100","author":"Tchou","year":"2004","journal-title":"Cancer"},{"key":"10.1111\/tbj.12418-BIB0038|tbj12418-cit-0038","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10689-005-4215-3","article-title":"The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation","volume":"4","author":"Metcalfe","year":"2005","journal-title":"Fam Cancer"},{"key":"10.1111\/tbj.12418-BIB0039|tbj12418-cit-0039","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1525-1497.2006.00461.x","article-title":"\u201cWhy take it if you don't have anything?\u201d breast cancer risk perceptions and prevention choices at a public hospital","volume":"21","author":"Salant","year":"2006","journal-title":"J Gen Intern Med"},{"key":"10.1111\/tbj.12418-BIB0040|tbj12418-cit-0040","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1158\/1055-9965.EPI-06-0910","article-title":"Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention","volume":"16","author":"Goldenberg","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1111\/tbj.12418-BIB0041|tbj12418-cit-0041","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/S0140-6736(00)03258-X","article-title":"Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group","volume":"356","author":"Narod","year":"2000","journal-title":"Lancet"},{"key":"10.1111\/tbj.12418-BIB0042|tbj12418-cit-0042","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","article-title":"Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial","volume":"286","author":"King","year":"2001","journal-title":"JAMA"},{"key":"10.1111\/tbj.12418-BIB0043|tbj12418-cit-0043","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1002\/cncr.20981","article-title":"Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction","volume":"103","author":"Melnikow","year":"2005","journal-title":"Cancer"},{"key":"10.1111\/tbj.12418-BIB0044|tbj12418-cit-0044","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1001\/archinte.161.13.1639","article-title":"Women's interest in chemoprevention for breast cancer","volume":"161","author":"Bastian","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1111\/tbj.12418-BIB0045|tbj12418-cit-0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1369-6513.2003.00195.x","article-title":"Development and evaluation of a breast cancer prevention decision aid for higher-risk women","volume":"6","author":"Stacey","year":"2003","journal-title":"Health Expect"},{"key":"10.1111\/tbj.12418-BIB0046|tbj12418-cit-0046","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ygyno.2009.06.006","article-title":"American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction","volume":"115","author":"Visvanathan","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1111\/tbj.12418-BIB0047|tbj12418-cit-0047","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2010.33.0258","article-title":"Benefit\/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50\u00a0years or older","volume":"29","author":"Freedman","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12418-BIB0048|tbj12418-cit-0048","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s12609-012-0082-8","article-title":"Tamoxifen vs. raloxifene vs. exemestane for chemoprevention","volume":"4","author":"Reimers","year":"2012","journal-title":"Curr Breast Cancer Rep."},{"key":"10.1111\/tbj.12418-BIB0049|tbj12418-cit-0049","first-page":"495S","article-title":"National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ","volume":"9","author":"Vogel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1111\/tbj.12418-BIB0050|tbj12418-cit-0050","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1093\/jnci\/djm223","article-title":"Projecting individualized absolute invasive breast cancer risk in African American women","volume":"99","author":"Gail","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/tbj.12418-BIB0051|tbj12418-cit-0051","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/jnci\/djr154","article-title":"Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women","volume":"103","author":"Matsuno","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/tbj.12418-BIB0052|tbj12418-cit-0052","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1006\/gyno.2001.6160","article-title":"Breast cancer risk assessment in indigent women at a public hospital","volume":"81","author":"Abu-Rustum","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1111\/tbj.12418-BIB0053|tbj12418-cit-0053","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/cncr.21164","article-title":"Barriers to minority participation in breast carcinoma prevention trials","volume":"104","author":"Grann","year":"2005","journal-title":"Cancer"}],"container-title":["The Breast Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftbj.12418","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/tbj.12418\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:27:53Z","timestamp":1643351273000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tbj.12418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,16]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,7]]}},"URL":"https:\/\/doi.org\/10.1111\/tbj.12418","relation":{},"ISSN":["1075-122X"],"issn-type":[{"type":"print","value":"1075-122X"}],"subject":[],"published":{"date-parts":[[2015,4,16]]}}}